REGENERON Aktie

 

SAN FRANCISCO, Aug. 14, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......

This timeline-focused notice highlights allegations that Regeneron's Phase III Fianlimab-Libtayo disclosures evolved from delayed event accrual to a protocol amendment and then a failed primary endpoint, with REGN investors allegedly absorbing substantial share-price losses. NEW YORK, Aug.......

NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or......

Zoghbi, Huda Y. - Aufsichtsrat - Tag der Transaktion: 2026-08-10...

Guarini, Kathryn - Aufsichtsrat - Tag der Transaktion: 2026-08-10...

SAN FRANCISCO, Aug. 12, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......

Control-person liability allegations focus on Regeneron executives' alleged authority over public clinical-trial statements and SEC disclosures as REGN shares fell $102.09 from the Class Period high. NEW YORK, Aug. 12, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead......

Series A co-led by Regeneron Ventures and Playground Global, with participation from RA Capital Management, Goldcrest Capital, Forge Life Science Partners, Godfrey Capital, Merck Global Health Innovation Fund, and Everbright Biofund Pipeline includes two wholly owned, half-life extended monoclonal antibodies targeting complementary pathways in atopic dermatitis, both expected to enter the clinic in 2027 ALAMEDA, Calif.--(BUSINESS WIRE)--#AI--Infinimmune, a biotechnology company developing antibody therapeutics derived directly from the human immune system, today announced the closing of a $75 million Series A financing co-led by Regeneron Ventures and Playground Global with participation from RA Capital Management, Goldcrest Capital, Forge Life Science Partners, Godfrey Capital, and Wild Tree Ventures. Existing investors Merck Global Health Innovation Fund, Everbright Biofund, Civilization Ventures, and Pear VC also participated. The financing will accelerate clinical development of Infinimmune's two lea...

SAN FRANCISCO, Aug. 11, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......

SAN FRANCISCO, Aug. 10, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......

Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results....

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980,......

SAN FRANCISCO, Aug. 6, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......

Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions....

Ryan Crowe Regeneron securities defendant liability allegations focus on investor-facing statements about the Phase III Fianlimab-Libtayo Study before REGN shares declined $102.09 per share from the Class Period high. NEW YORK, Aug. 5, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies......

Regeneron hat mit seinen jüngsten Quartalszahlen die Erwartungen deutlich übertroffen. Dupixent, Eylea in der höheren Dosierung und Libtayo wachsen kräftig, während die Aktie ihre monatelange Schwächephase beendet. Nach dem charttechnischen Befreiungsschlag könnte nun die nächste Rally starten....

SAN FRANCISCO, Aug. 4, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......

NEW YORK, Aug. 4, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead......